Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Cynomolgus Nectin-4, His Tag (Cat. No. NE4-C52H4) with an affinity constant of 824 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Enfortumab vedotin | AGS-22C3E; ASG-22CE; AGS-22ME; AGS-22C3; AGS-M6; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22M6E | Approved | Agensys, Seattle Genetics | Padcev | Canada | Urinary Bladder Neoplasms | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University | Neoplasms | Details | |
| BT-8009 | BT-8009 | Phase 2 Clinical | Bicycle Tx Ltd | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
| 9MW2821 | 9MW2821; 9-MW2821; 9-MW-2821; 9MW-2821 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
| SBT-6290 | SBT-6290 | Phase 2 Clinical | Silverback Therapeutics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
